IPATential150: efficacy and safety from the Phase III study of ipatasertib▼ plus abiraterone vs placebo plus abiraterone in metastatic castration-resistant prostate cancer
IPATential150 is a Phase III, randomised, double-blind study evaluating the efficacy and safety of adding ipatasertib▼ to abiraterone and prednisone in patients with previously untreated metastatic castration-resistant prostate cancer. Here, we present the rPFS in ITT and PTEN-loss by IHC populations, the co-primary endpoints, as well as the OS, ORR, PSA response rate, time to PSA progression/pain progression/initiation of chemotherapy, and rPFS in PTEN-loss by NGS populations.